Search
+
    SEARCHED FOR:

    ATOPIC DERMATITIS

    J&J acquires experimental skin disorder drug for $1.25 billion

    NUMAB THERAPEUTICS-JOHNSON&JOHNSON/M&A (UPDATE 2, PIX)UPDATE 2-J&J acquires experimental skin disorder drug for $1.25 billion

    Sanofi looks for accelerated growth in India; plans fast-tracking of product pipeline

    Sanofi, a leading French pharmaceutical company, aims to expand its presence in the Indian market by introducing new drugs, enhancing localization efforts, and collaborating with domestic firms. Managing Director Rodolfo Hrosz highlights the significant growth potential in India and emphasizes the company's focus on addressing the diabetes segment.

    Glenmark partners with Pfizer to launch abrocitinib in India to treat atopic dermatitis

    Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It is also approved by the USFDA, European Medicines Agency (EMA), and other regulatory agencies.

    Believe it or not, your food & pollen allergies may be protecting you from catching Covid

    New research said that people with atopic diseases have 25% lower odds of contracting Covid.

    Jayalalithaa death: AIIMS panel gives clean chit to Apollo Hospital, says "correct" medical procedures followed

    AIIMS panel of doctors has asserted that the treatment provided to late Tamil Nadu Chief Minister Jayalalithaa was as per "correct medical practice and no errors" have been found in the care provided.

    How to deal with itchy eyes

    Itchy eyes related problems can be triggered by exposure to pollen, animal fur, mould, dust mites, make-up, or eye drops. The body reacts to the trigger by releasing histamine, causing the blood vessels in the eye/or around the eyes to dilate and irritating the nerve endings so the eyes water.

    The Economic Times
    BACK TO TOP